Brainstorm Cell Therapeutics

(OTC) BCLI

Current Price$0.65

Market Cap$7.25M

Since IPO (2003)-87%

5 YearN/A

1 YearN/A

1 Month-25%

Brainstorm Cell Therapeutics Financials at a Glance

Market Cap

$7.25M

Revenue (TTM)

$0.00

Net Income (TTM)

$10.31M

EPS (TTM)

$-1.20

P/E Ratio

-0.55

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$0.65

Volume

1,870

Open

$0.62

Price

$0.65

Volume

1,870

Open

$0.62

Previous Close

$0.65

Daily Range

$0.62 - $0.67

52-Week Range

$0.46 - $0.97

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$0.65

Volume

1,870

Open

$0.62

Previous Close

$0.65

Daily Range

$0.62 - $0.67

52-Week Range

$0.46 - $0.97

BCLI News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Brainstorm Cell Therapeutics

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Chaim Lebovits

Website

www.brainstorm-cell.com

Headquarters

New York City, NY 10019, US

BCLI Financials

Key Financial Metrics (TTM)

Gross Margin

Operating Margin

Net Income Margin

Return on Equity

Return on Capital

97%

Return on Assets

-14%

Earnings Yield

-1.82%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$7.25M

Shares Outstanding

11.03M

Volume

1.87K

Avg. Volume

18.57K

Financials (TTM)

Gross Profit

$0.00

Operating Income

$9.95M

EBITDA

$9.75M

Operating Cash Flow

$6.97M

Capital Expenditure

$0.00

Free Cash Flow

$6.97M

Cash & ST Invst.

$29.00K

Total Debt

$208.00K

Brainstorm Cell Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q4 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

$48.00K

+9.4%

Gross Margin

0.00%

N/A

Market Cap

$7.25M

N/A

Market Cap/Employee

$268.69K

N/A

Employees

N/A

Net Income

$2.43M

+18.1%

EBITDA

$2.20M

+30.0%

Quarterly Fundamentals

Name

Q4 2025YOY CHG

Net Cash

$1.15M

-115.0%

Accounts Receivable

$86.00K

+36.5%

Inventory

$0.00

N/A

Long Term Debt

$208.00K

+21.6%

Short Term Debt

$1.18M

+114.0%

Return on Assets

-14.42%

N/A

Return on Invested Capital

96.71%

N/A

Free Cash Flow

$740.00K

+29.4%

Operating Cash Flow

$740.00K

+29.4%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

BCDABioCardia, Inc.

BCDABioCardia, Inc.$1.13+1.80%

ADXNAddex Therapeutics Ltd

ADXNAddex Therapeutics Ltd$6.93+0.43%

CDIOCardio Diagnostics Holdings, Inc.

CDIOCardio Diagnostics Holdings, Inc.$1.97+4.79%

VYNEVYNE Therapeutics Inc.

VYNEVYNE Therapeutics Inc.$0.66+2.31%

ACXPAcurx Pharmaceuticals, Inc.

ACXPAcurx Pharmaceuticals, Inc.$2.13-1.39%

ADILAdial Pharmaceuticals, Inc.

ADILAdial Pharmaceuticals, Inc.$1.60+3.23%

HCWBHCW Biologics Inc.

HCWBHCW Biologics Inc.$0.41-9.25%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

CNSPCns Pharmaceuticals

CNSPCns Pharmaceuticals$7.84+2.39%

GBTGGlobal Business Travel Group

GBTGGlobal Business Travel Group$9.34+0.58%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$13.18+0.01%

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF$5.69-0.00%

SOFISoFi Technologies

SOFISoFi Technologies$16.20-0.01%

IBITiShares Bitcoin Trust

IBITiShares Bitcoin Trust$45.40+0.02%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$64.91-0.01%

Questions About BCLI

What is the current price of Brainstorm Cell Therapeutics?

Brainstorm Cell Therapeutics is trading at $0.65 per share.

What is the 52-week range for Brainstorm Cell Therapeutics?

Over the past 52 weeks, Brainstorm Cell Therapeutics has traded between $0.46 and $0.97.

How much debt does Brainstorm Cell Therapeutics have?

As of the most recent reporting period, Brainstorm Cell Therapeutics reported total debt of $1.18M.

How much cash does Brainstorm Cell Therapeutics have on hand?

Brainstorm Cell Therapeutics reported $29,000 in cash and cash equivalents in its most recent financial results.

What is Brainstorm Cell Therapeutics’s dividend yield?

Brainstorm Cell Therapeutics does not currently have a dividend yield.

Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Financials at a Glance

BCLI News

Brainstorm Posts 43% EPS Gain in Q2

Why BrainStorm Cell Therapeutics Blasted 27.7% Higher Today

Why BrainStorm Cell Therapeutics Stock Imploded Today

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Brainstorm Cell Therapeutics

BCLI Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Brainstorm Cell Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About BCLI

What is the current price of Brainstorm Cell Therapeutics?

What is the 52-week range for Brainstorm Cell Therapeutics?

How much debt does Brainstorm Cell Therapeutics have?

How much cash does Brainstorm Cell Therapeutics have on hand?

What is Brainstorm Cell Therapeutics’s dividend yield?

Premium Investing Services